Edward Groleau

Aug 14, 2024 | clinicalleader.com | Harriet Gray Stephens |Edward Groleau |Dan Schell |J.C. Wilson

The Pros And Cons Of Synthetic Control Arms In Clinical TrialsExplore how synthetic control arms (SCAs) are being used in clinical trials, the views of regulators, and the advantages and limitations of SCAs in practice. Strengthening Pathways For Cell And Gene TherapiesThis report aims to spur informed discussions on the future trajectory of cell and gene therapies and their pivotal role in shaping the future of healthcare.

Jan 31, 2024 | clinicalleader.com | Edward Groleau

EDC has become a premier clinical technology in improving data accuracy and reducing site burden through time and resource conservation. But which EDC do you choose? The market for clinical technologies has produced more and more solutions in recent years, making the selection process complex. Don’t miss the Clinical Leader Solutions Expo where leading EDC suppliers will showcase their latest technologies and solutions via a virtual, interactive platform. Registration is free.

Jan 18, 2024 | outsourcedpharma.com | Louis Garguilo |Antony Hitchcock |AGH Bioconsulting |Edward Groleau

The distribution of critical cell samples requires an agile strategy with contingency planning and regulatory expertise to ensure seamless delivery on time and within specifications. Unexpected delays, international customs, and final mile delivery can all pose risks to delivering cell samples within a 48-hour stability lifespan. Review an innovative solution to safeguard the transport of urgent samples from Canada to the U.S. that resulted in an overall 42-hour turnaround time (TAT). Learn more.